These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 34970268)

  • 1. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of the novel immune risk scoring system related to CD8
    Zhang G; Yin Z; Fang J; Wu A; Chen G; Cao K
    Cancer Cell Int; 2023 Jun; 23(1):124. PubMed ID: 37349706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An miRNA signature associated with tumor mutation burden in endometrial cancer.
    Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs.
    Li N; Yu K; Lin Z; Zeng D
    Exp Biol Med (Maywood); 2022 Feb; 247(3):221-236. PubMed ID: 34704492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
    Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
    Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
    Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
    Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
    Lai J; Xu T; Yang H
    BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
    Miao C; Fang X; Chen Y; Zhao Y; Guo Q
    Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
    Liu W; Sun L; Zhang J; Song W; Li M; Wang H
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
    Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
    Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
    Liu J; Lu J; Li W
    Front Immunol; 2021; 12():738068. PubMed ID: 34630418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
    Zhou M; Zhang Z; Zhao H; Bao S; Sun J
    BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.